Electroporation in DNA vaccination protocols against cancer

Pieranna Chiarella, Vito Michele Fazio, Emanuela Signori

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Since conventional therapeutic approaches in cancer are highly invasive they hardly prolong patient survival for more than few months. Having the ability to stimulate both cellular and humoural immune responses, immunisation with naked plasmid DNA encoding tumour-associated antigens or tumour-specific antigens has recently reported a plethora of advantages, and the improvement of vaccine efficacy has emerged as a goal in the development of DNA vaccination as anti-tumour therapy. Nevertheless, because of their poor immunogenicity when administered as unformulated intramuscular injections, plasmid DNA vaccines need to be improved. Recent data suggest that the DNA vaccine efficacy may significantly be increased by electroporation. This review highlights the recent literature that supports electroporation as an effective strategy to improve DNA-based vaccination protocols, investigating the most relevant studies, recently developed for the applications of DNA vaccine electrotransfer against tumours in pre-clinical and clinical studies.

Original languageEnglish
Pages (from-to)291-299
Number of pages9
JournalCurrent Drug Metabolism
Volume14
Issue number3
DOIs
Publication statusPublished - Mar 2013

Fingerprint

DNA Vaccines
Electroporation
Tumors
Vaccination
Neoplasm Antigens
DNA
Plasmids
Neoplasms
Intramuscular Injections
Immunization
Antigens
Cellular Immunity
Vaccines
Survival
Therapeutics

Keywords

  • Cancer
  • DNA vaccine
  • Electroporation
  • Immune response
  • Tumour antigen

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry

Cite this

Electroporation in DNA vaccination protocols against cancer. / Chiarella, Pieranna; Fazio, Vito Michele; Signori, Emanuela.

In: Current Drug Metabolism, Vol. 14, No. 3, 03.2013, p. 291-299.

Research output: Contribution to journalArticle

Chiarella, Pieranna ; Fazio, Vito Michele ; Signori, Emanuela. / Electroporation in DNA vaccination protocols against cancer. In: Current Drug Metabolism. 2013 ; Vol. 14, No. 3. pp. 291-299.
@article{4c3868b8a2744ce3aa7dc9cb7394f382,
title = "Electroporation in DNA vaccination protocols against cancer",
abstract = "Since conventional therapeutic approaches in cancer are highly invasive they hardly prolong patient survival for more than few months. Having the ability to stimulate both cellular and humoural immune responses, immunisation with naked plasmid DNA encoding tumour-associated antigens or tumour-specific antigens has recently reported a plethora of advantages, and the improvement of vaccine efficacy has emerged as a goal in the development of DNA vaccination as anti-tumour therapy. Nevertheless, because of their poor immunogenicity when administered as unformulated intramuscular injections, plasmid DNA vaccines need to be improved. Recent data suggest that the DNA vaccine efficacy may significantly be increased by electroporation. This review highlights the recent literature that supports electroporation as an effective strategy to improve DNA-based vaccination protocols, investigating the most relevant studies, recently developed for the applications of DNA vaccine electrotransfer against tumours in pre-clinical and clinical studies.",
keywords = "Cancer, DNA vaccine, Electroporation, Immune response, Tumour antigen",
author = "Pieranna Chiarella and Fazio, {Vito Michele} and Emanuela Signori",
year = "2013",
month = "3",
doi = "10.2174/1389200211314030004",
language = "English",
volume = "14",
pages = "291--299",
journal = "Current Drug Metabolism",
issn = "1389-2002",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Electroporation in DNA vaccination protocols against cancer

AU - Chiarella, Pieranna

AU - Fazio, Vito Michele

AU - Signori, Emanuela

PY - 2013/3

Y1 - 2013/3

N2 - Since conventional therapeutic approaches in cancer are highly invasive they hardly prolong patient survival for more than few months. Having the ability to stimulate both cellular and humoural immune responses, immunisation with naked plasmid DNA encoding tumour-associated antigens or tumour-specific antigens has recently reported a plethora of advantages, and the improvement of vaccine efficacy has emerged as a goal in the development of DNA vaccination as anti-tumour therapy. Nevertheless, because of their poor immunogenicity when administered as unformulated intramuscular injections, plasmid DNA vaccines need to be improved. Recent data suggest that the DNA vaccine efficacy may significantly be increased by electroporation. This review highlights the recent literature that supports electroporation as an effective strategy to improve DNA-based vaccination protocols, investigating the most relevant studies, recently developed for the applications of DNA vaccine electrotransfer against tumours in pre-clinical and clinical studies.

AB - Since conventional therapeutic approaches in cancer are highly invasive they hardly prolong patient survival for more than few months. Having the ability to stimulate both cellular and humoural immune responses, immunisation with naked plasmid DNA encoding tumour-associated antigens or tumour-specific antigens has recently reported a plethora of advantages, and the improvement of vaccine efficacy has emerged as a goal in the development of DNA vaccination as anti-tumour therapy. Nevertheless, because of their poor immunogenicity when administered as unformulated intramuscular injections, plasmid DNA vaccines need to be improved. Recent data suggest that the DNA vaccine efficacy may significantly be increased by electroporation. This review highlights the recent literature that supports electroporation as an effective strategy to improve DNA-based vaccination protocols, investigating the most relevant studies, recently developed for the applications of DNA vaccine electrotransfer against tumours in pre-clinical and clinical studies.

KW - Cancer

KW - DNA vaccine

KW - Electroporation

KW - Immune response

KW - Tumour antigen

UR - http://www.scopus.com/inward/record.url?scp=84877960546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877960546&partnerID=8YFLogxK

U2 - 10.2174/1389200211314030004

DO - 10.2174/1389200211314030004

M3 - Article

C2 - 23116110

AN - SCOPUS:84877960546

VL - 14

SP - 291

EP - 299

JO - Current Drug Metabolism

JF - Current Drug Metabolism

SN - 1389-2002

IS - 3

ER -